Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer
* Registry
* Multicenter, prospective observational study
* Observe adverse events and efficacy in recruited patients for 3 years under real world settings.
Metastatic Colorectal Cancer
DRUG: FOLFIRI, target agent
percentage of use FOLFIRI regimen and target agents, through study completion, 3 years
* Registry
* Multicenter, prospective observational study
* Observe adverse events and efficacy in recruited patients for 3 years under real world settings.